McNeill Jonathan sold $370K of CBIO
McNeill Jonathan (President and COO) sold 20,549 shares of CRESCENT BIOPHARMA, INC. (CBIO) at $17.99 ($0.37M total) on 2026-06-22 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is pre-arranged under a Rule 10b5-1 plan, which typically lowers the informational content versus unscheduled selling.
Market read
A single insider sale at ~$369.7K is disclosed; likely more relevant for sentiment monitoring than for a fundamental reprice.
What to watch
The article provides no context on total insider holdings changes beyond the post-sale figure, nor any concurrent operational/clinical updates.
Background
The article is an SEC Form 4 insider transaction for Crescent Biopharma, filed via EDGAR.
Ticker impact
Crescent Biopharma Form 4 shows President/COO McNeill Jonathan sold 20,549 shares at $17.99 under a 10b5-1 plan.
Likely limited near-term impact; any effect should be small and sentiment-driven.
The filing is a Form 4 with an explicitly pre-arranged 10b5-1 plan, reducing interpretive signal versus discretionary selling.
Market effects
No clear sector read-through; this is company-specific insider transaction data.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, repeated insider sales can still coincide with internal expectations of near-term risk, so traders may watch for follow-on disclosures.
Key entities
- issuerCrescent Biopharma, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderMcNeill Jonathan
President and COO who sold shares under a pre-arranged 10b5-1 plan.
